Press release
Esophageal Squamous Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2024
DelveInsight's, "Esophageal Squamous Cell Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report
• DelveInsight's Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
• The leading companies working in the Esophageal Squamous Cell Carcinoma Market include BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc. and others.
• Promising Esophageal Squamous Cell Carcinoma Pipeline Therapies in the various stages of development include Sitravatinib, Tislelizumab, Docetaxel, Irinotecan, SI-B001, Cisplatin, Paclitaxel, and others.
• December 2023: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Tiragolumab and Atezolizumab. The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
• December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Pembrolizumab, Lenvatinib, Cisplatin, Oxaliplatin, and Levoleucovorin. The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma. The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
• December 2023: BeiGene announced a study of Phase 2 clinical trials for LBL-007 and Tislelizumab. This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Request a sample and discover the recent advances in Esophageal Squamous Cell Carcinoma Treatment Drugs @ Esophageal Squamous Cell Carcinoma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Esophageal Squamous Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Esophageal Squamous Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Esophageal Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Esophageal Squamous Cell Carcinoma Overview
Esophageal Squamous Cell Carcinoma is the most common form of esophageal cancer worldwide. Although it is no longer the most common form of esophageal carcinoma in Western societies, ESCC continues to be the most prevalent type of esophageal cancer in the East, representing 90% of all cancers in most Asian, African, and Eastern European countries. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics.
Find out more about Esophageal Squamous Cell Carcinoma Therapeutics Assessment @ Esophageal Squamous Cell Carcinoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Esophageal Squamous Cell Carcinoma Emerging Drugs Profile
• Tislelizumab: BeiGene
• Serplulimab: Shanghai Henlius Biotech
Esophageal Squamous Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the Esophageal Squamous Cell Carcinoma therapies. The Esophageal Squamous Cell Carcinoma companies which have their Esophageal Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, BeiGene.
DelveInsight's Esophageal Squamous Cell Carcinoma pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Learn more about the emerging Esophageal Squamous Cell Carcinoma Pipeline Therapies @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report
• Coverage- Global
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc. and others.
• Esophageal Squamous Cell Carcinoma Pipeline Therapies- Sitravatinib, Tislelizumab, Docetaxel, Irinotecan, SI-B001, Cisplatin, Paclitaxel, and others.
Dive deep into rich insights for new drugs for Esophageal Squamous Cell Carcinoma Treatment, Visit @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Esophageal Squamous Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Esophageal Squamous Cell Carcinoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tislelizumab: BeiGene
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RAPA-201: Rapa Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. SGN-B6A: Seagen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Esophageal Squamous Cell Carcinoma Key Companies
21. Esophageal Squamous Cell Carcinoma Key Products
22. Esophageal Squamous Cell Carcinoma- Unmet Needs
23. Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers
24. Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion
25. Esophageal Squamous Cell Carcinoma Analyst Views
26. Esophageal Squamous Cell Carcinoma Key Companies
27. Appendix
For further information on the Esophageal Squamous Cell Carcinoma Pipeline therapeutics, reach out to Esophageal Squamous Cell Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
https://www.delveinsight.com/report-store/glaucoma-market
https://www.delveinsight.com/report-store/uveitis-market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
https://www.delveinsight.com/report-store/nephrotic-syndrome-market
https://www.delveinsight.com/report-store/short-bowel-syndrome-market
https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
https://www.delveinsight.com/report-store/aplastic-anemia-market
https://www.delveinsight.com/report-store/cystic-fibrosis-market
https://www.delveinsight.com/report-store/heart-failure-market
https://www.delveinsight.com/report-store/peanut-allergy-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/post-operative-pain-management-market
https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report
• DelveInsight's Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
• The leading companies working in the Esophageal Squamous Cell Carcinoma Market include BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc. and others.
• Promising Esophageal Squamous Cell Carcinoma Pipeline Therapies in the various stages of development include Sitravatinib, Tislelizumab, Docetaxel, Irinotecan, SI-B001, Cisplatin, Paclitaxel, and others.
• December 2023: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Tiragolumab and Atezolizumab. The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
• December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Pembrolizumab, Lenvatinib, Cisplatin, Oxaliplatin, and Levoleucovorin. The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma. The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
• December 2023: BeiGene announced a study of Phase 2 clinical trials for LBL-007 and Tislelizumab. This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Request a sample and discover the recent advances in Esophageal Squamous Cell Carcinoma Treatment Drugs @ Esophageal Squamous Cell Carcinoma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Esophageal Squamous Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Esophageal Squamous Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Esophageal Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Esophageal Squamous Cell Carcinoma Overview
Esophageal Squamous Cell Carcinoma is the most common form of esophageal cancer worldwide. Although it is no longer the most common form of esophageal carcinoma in Western societies, ESCC continues to be the most prevalent type of esophageal cancer in the East, representing 90% of all cancers in most Asian, African, and Eastern European countries. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics.
Find out more about Esophageal Squamous Cell Carcinoma Therapeutics Assessment @ Esophageal Squamous Cell Carcinoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Esophageal Squamous Cell Carcinoma Emerging Drugs Profile
• Tislelizumab: BeiGene
• Serplulimab: Shanghai Henlius Biotech
Esophageal Squamous Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the Esophageal Squamous Cell Carcinoma therapies. The Esophageal Squamous Cell Carcinoma companies which have their Esophageal Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, BeiGene.
DelveInsight's Esophageal Squamous Cell Carcinoma pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Learn more about the emerging Esophageal Squamous Cell Carcinoma Pipeline Therapies @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report
• Coverage- Global
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc. and others.
• Esophageal Squamous Cell Carcinoma Pipeline Therapies- Sitravatinib, Tislelizumab, Docetaxel, Irinotecan, SI-B001, Cisplatin, Paclitaxel, and others.
Dive deep into rich insights for new drugs for Esophageal Squamous Cell Carcinoma Treatment, Visit @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Esophageal Squamous Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Esophageal Squamous Cell Carcinoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tislelizumab: BeiGene
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RAPA-201: Rapa Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. SGN-B6A: Seagen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Esophageal Squamous Cell Carcinoma Key Companies
21. Esophageal Squamous Cell Carcinoma Key Products
22. Esophageal Squamous Cell Carcinoma- Unmet Needs
23. Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers
24. Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion
25. Esophageal Squamous Cell Carcinoma Analyst Views
26. Esophageal Squamous Cell Carcinoma Key Companies
27. Appendix
For further information on the Esophageal Squamous Cell Carcinoma Pipeline therapeutics, reach out to Esophageal Squamous Cell Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
https://www.delveinsight.com/report-store/glaucoma-market
https://www.delveinsight.com/report-store/uveitis-market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
https://www.delveinsight.com/report-store/nephrotic-syndrome-market
https://www.delveinsight.com/report-store/short-bowel-syndrome-market
https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
https://www.delveinsight.com/report-store/aplastic-anemia-market
https://www.delveinsight.com/report-store/cystic-fibrosis-market
https://www.delveinsight.com/report-store/heart-failure-market
https://www.delveinsight.com/report-store/peanut-allergy-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/post-operative-pain-management-market
https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
